Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

Written by: | no-reply@reuters.com | Dated: Wednesday, May 30th, 2018

 

(Reuters) – AstraZeneca’s first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

The drug is currently approved as an add-on treatment for severe eosinophilic asthma in the United States, the European Union, Japan and several other countries.

Fasenra failed to meet its target in the final-stage trial, named Galathea, this month.

 

Reporting By Justin George Varghese in Bengaluru; Editing by David Goodman

 

Reuters source:

https://www.reuters.com/article/us-astrazeneca-fasenra/astrazeneca-drug-fasenra-fails-to-achieve-main-goal-in-copd-trial-idUSKCN1IV0M3

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2018 Focus: Biotech, Payer Access, DTC and more!

Subscribe

Ad Right Bottom

Main Navigation